PILOT STUDY FOR IDENTIFYING URINARY PROSTATE CANCER BIOMARKERS

鉴定尿路前列腺癌生物标志物的试点研究

• 批准号: 8170711
• 负责人: ALVIN Y LIU
• 金额: $ 3.21万
• 依托单位: BATTELLE PACIFIC NORTHWEST LABORATORIES
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8170711
• 关键词: Biological Markers; Biopsy; Computer Retrieval of Information on Scientific Projects Database; Development; Funding; Genomics; Grant; Institution; Investigation; Malignant Neoplasms; Malignant neoplasm of prostate; Pilot Projects; Proteins; Proteomics; Research; Research Personnel; Resources; Sampling; Screening for cancer; Source; Technology; Testing; United States National Institutes of Health; Urine; cancer cell; multiple reaction monitoring; serum PSA; urinary

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Urinary prostate cancer protein biomarkers are important for early cancer detection. A urine test at this point can significantly reduce the number of unnecessary biopsies done as a result of elevated serum PSA. The application of genomics to cancer cells has allowed the identification of a number of candidate biomarkers for further investigations. This pilot study will utilize the advanced targeted proteomic technology using multiple reaction monitoring (MRM) under the resource center for testing the discriminatory power of identified cancer proteins in urine samples. The application is also anticipated to drive further development and optimization of the targeted MRM technology.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 尿前列腺癌蛋白质生物标志物对于早期癌症检测很重要。 此时进行尿检可以显着减少因血清 PSA 升高而进行的不必要的活检次数。 基因组学在癌细胞中的应用使得能够鉴定出许多候选生物标志物以供进一步研究。 这项先导研究将利用资源中心的先进靶向蛋白质组学技术，利用多重反应监测（MRM）技术，测试尿液样本中已识别癌症蛋白的辨别能力。 该应用预计还将推动目标 MRM 技术的进一步开发和优化。